Owhofasa Agbedia, MD, MPH, FACP (@fasaagbedia) 's Twitter Profile
Owhofasa Agbedia, MD, MPH, FACP

@fasaagbedia

Hematologist/Medical Oncologist | Interest in hematological malignancies | Tweets/opinions are mine ≠ medical advice #CART #Lymphoma #lysm

ID: 1362315860

calendar_today18-04-2013 16:14:29

344 Tweet

850 Followers

2,2K Following

Owhofasa Agbedia, MD, MPH, FACP (@fasaagbedia) 's Twitter Profile Photo
Owhofasa Agbedia, MD, MPH, FACP
@fasaagbedia

a year ago

Given the differential efficacy of polatuzumab against DLBCL subtypes (on account of ABC-specific vulnerability of CD79b targeting and differential efficacy of the polatuzumab payload, MMAE) precision medicine is warranted for untreated DLBCL #lysm nejm.org/doi/full/10.10…